Prognostic Role of HER2 Amplification and Mutations in Metastatic Colorectal Cancer: Insights from Eight Randomized Trials
Highlight
1. HER2 amplification/overexpression occurs in approximately 5% of RAS/BRAF wild-type metastatic colorectal cancers (mCRCs) and is associated with worse progression-free and overall survival.
2. HER2 mutations, although less common (2% of HER2-negative tumors), similarly link to poorer overall survival.
3. Neither HER2 amplification nor mutation status predicts benefit from chemotherapy combined with bevacizumab or anti-EGFR monoclonal antibodies.
4. These findings support HER2 alteration status as a negative prognostic factor, not predictive of biologic agent efficacy, in proficient mismatch repair (pMMR)/microsatellite stable (MSS) RAS/BRAF wild-type mCRC.
Study Background and Disease Burden
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.